查詢結果分析
相關文獻
- The Therapeutic Effect of Inhaled Nitric Oxide in Neonatal Persistent Pulmonary Hypertension with and without Congenital Heart Disease
- 一氧化氮(Nitric Oxide Therapy)對新生兒肺高壓的應用
- Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of Term Infants
- Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn: Four-Year Experience in a Single Medical Center
- 一氧化氮(NO)用於持續性肺高壓症(PPHN)的治療效果
- 一氧化氮在新生兒肺高壓的治療成效
- 一氧化氮吸入療法治療新生兒肺高壓症候群
- 以吸入一氧化氮(Nitric Oxide)治療新生兒肺疾患
- Factors Associated with High-frequency Oscillatory Ventilation Response in Infants with Respiratory Failure
- Diagnostic Pitfalls in Congenital Right Diaphragmatic Hernia
頁籤選單縮合
題名 | The Therapeutic Effect of Inhaled Nitric Oxide in Neonatal Persistent Pulmonary Hypertension with and without Congenital Heart Disease=吸入型一氧化氮用於治療合併或不合併先天性心臟病的新生兒持續性肺高壓之效果評估 |
---|---|
作 者 | 許馨月; 黃崇濱; 陳志誠; 黃新純; 劉倢安; 鍾美勇; | 書刊名 | Clinical Neonatology |
卷期 | 13:1 民95.06 |
頁次 | 頁1-5 |
分類號 | 417.517 |
關鍵詞 | 一氧化氮; 心臟病; 新生兒; 肺高壓; Inhaled nitric oxide; Persistent pulmonary hypertension of the newborn; Acyanotic congenital heart disease; |
語文 | 英文(English) |
英文摘要 | Objectives: To assess the therapeutic effect of inhaled nitric oxide (iNO) for persistent pulmonary hypertension of the newborn (PPHN) in infants without congenital heart disease and infants with severe acyanotic congenital heart disease. Methods: Thirty-three patients with persistent pulmonary hypertension were enrolled in this study. All cases were compatible with the diagnostic criteria of PPHN and were divided into two groups-Group 1 was neonates without congenital heart disease (n=21) and Group 2 was neonates with severe acyanotic congenital heart disease (n=12). All patients underwent iNO therapy from 20 to 60 ppm after definite diagnosis of pulmonary hypertension. Improvement in pulse oximetry (SpO2) and the oxygenation index (OI) served as indicators of the therapeutic effect. We also recorded changes in the mean arterial pressure (MAP) to investigate the possible side effects of iNO therapy. Results: The mean baseline SpO2 was 75.5±7.9% in Group 1 and 75.9±9.8% in Group 2. After administration of iNO for three hours, the SpO2 in Group 1 increased significantly to 91.6 ± 10.2% (p<0.01) but remained low in Group 2 ( SpO2 was 77.5±11.8% and p=0.762). The OI was also significantly reduced in Group 1 after iNO therapy (p<0.01). The MAP in the two groups showed no significant change before and after iNO treatment. The nitrogen dioxide concentration was below 3 ppm in all cases. Conclusions: In neonates with PPHN, early iNO therapy improves oxygenation without short-term side effect. Nevertheless, patients with PPHN complicated by congenital heart disease did not achieve the same excellent results. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。